Company intelligence / Profile preview

Humabs BioMed

Bellinzona, Ticino, Switzerlandhumabs.com ↗

Ownership: Private
Development stage: Other

Overview

Humabs BioMed's antibody discovery platform has produced clinical-stage monoclonal antibodies, including those against Ebola, COVID-19, hepatitis B/D, and influenza, with several assets undergoing Phase 1/2 clinical trials as part of Vir Biotechnology’s pipeline. Their COVID-19 antibody, sotrovimab, received global emergency use authorization and commercial approval.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Partnerships

U.S. Biomedical Advanced Research and Development Authority (BARDA)Institute for Research in Biomedicine (IRB) Bellinzona

Beyond the preview

Go deeper on Humabs BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humabs BioMed.